Search results
What to Know About Burrow’s Editor-Loved MCM Furniture
Apartment Therapy via Yahoo News· 3 days agoThe fabric sofas have long been reviewed as pet-friendly, and that is by design: Its tightly woven...
Another Study Finds CRISPR Gene Therapy Fights Sickle Cell | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 3 days ago“It’s encouraging that this gene-editing treatment continues to show promising efficacy for sickle...
Study finds air pollution can increase cardiovascular risk for cancer patients
Medical Xpress· 3 days agoModern therapies have extended the lives of many cancer patients; however, survivors often live with...
Antidandruff shampoo may help combat some types of hair loss
Washington Post· 9 hours agoOn Instagram and TikTok, some dermatologists are praising an off-label use for certain antidandruff...
The Boys Season 4, Episode 3 Review
CBR.com· 6 days agoThe following contains discussion of graphic violence and self-harm, along with spoilers from The Boys, Season 4, Episode 3, "We'll Keep the Red Flag...
Groundbreaking cancer treatment may trigger more cancer – but here’s why you shouldn’t worry
The Conversation· 2 days agoIn the last few decades, scientists have finally learned to harness the immune system to successfully treat cancer. Car-T therapy, short for “chimeric antigen receptor T-cell ...
Céline Dion’s Doctor Makes Plea for More Stiff-Person Syndrome Research (Exclusive)
People via Yahoo News· 5 days ago“The awareness that we see with Céline bringing this to the general population… people are going to...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update
ETF DAILY NEWS· 6 days agoAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) saw a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 707,800 shares, ...
What Does FDA's Draft Platform Guidance Mean For CGT Companies?
BioresearchOnline· 5 days agoThe U.S. FDA released the much-anticipated draft guidance Platform Technology Designation Program...
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com
Investing.com· 1 day agoSilence Therapeutics plc (NASDAQ:SLN), a biotech firm focusing on RNA interference (RNAi) therapies,...